The medical and American plate rose sharply

Synthetic Biology: Who Will Emerge as the Winner?

The 21st century is the century of biology. Synthetic biology is believed to be a ‘World Changing’ industry. But the potential risks like cost control and commercialization pathways are fatefully tied to the ups and downs of countless investment decisions and the destiny of the many new start-ups getting involved. We look forward to seeing an emerging ‘giant’ on the horizon of this exciting industry.

Sino Biopharm and Boehringer Ingelheim Sign Option and License Deal for Six Cancer Programs

Sino Biopharmaceutical（中国生物制药）and Boehringer Ingelheim（勃林格殷格翰）announced an option and license agreement on November 4 covering six preclinical cancer programs. Sino Biopharm will receive USD 358 million in upfront and near-term payments and may receive up to USD 7 billion in additional option, development, regulatory and commercial milestone payments.

Wantai Launches Nine-Valent HPV Vaccine Cecolin 9 in Thailand

Wantai Biological（万泰生物）said on November 2 that its nine-valent HPV vaccine, Cecolin 9（馨可宁9）, had launched in Thailand. The product was jointly developed by its subsidiary Xiamen Innovax Biotech（厦门万泰沧海生物技术有限公司）and Xiamen University（厦门大学）.

EqualOcean｜China's Top 20 ESG Performers Among Private Enterprises（Part III）

Private enterprises are actively embracing the transformative era

Bloomage: Injecting Biotechnology into Beauty Care

Listed on the Chinese Star Market in November 2019, Bloomage was trading at CNY 138.01 as of June 24, 2020, over 38% higher than the IPO price of CNY 100.